Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Wolfe Research Downgrades AbbVie to Peer Perform

Wolfe Research Downgrades AbbVie to Peer Perform

Wolfe Research analyst Tim Anderson downgrades AbbVie (NYSE:ABBV) from Outperform to Peer Perform.

byBenzinga Newsdesk

February 22, 2023

1 minute read

Wolfe Research analyst Tim Anderson downgrades AbbVie (NYSE:ABBV) from Outperform to Peer Perform.

Can AI Beat Humans In Understanding Language? Tencent And Alibaba’s AI Models Can

By Anusuya Lahiri

November 29, 7:40 AM

Alibaba Group Holding Limited (NYSE: BABA) and Tencent Holding Ltd's (OTC: TCEHY) artificial intelligence (AI) models understand the Chinese language better than humans, a study suggested.

ADBE

HC Wainwright & Co. Initiates Coverage On Icecure Medical with Buy Rating, Announces Price Target of $3

By Benzinga Newsdesk

March 20, 7:12 AM

HC Wainwright & Co. analyst Yi Chen initiates coverage on Icecure Medical (NASDAQ:ICCM) with a Buy rating and announces Price Target of $3.

ICCM

Bristol Myers Squibb Strengthens Oncology Portfolio With Mirati Therapeutics’ $5B Deal

By Vandana Singh

October 9, 9:07 AM

Bristol Myers Squibb & Co (NYSE: BMY) has agreed to acquire Mirati Therapeutics Inc (NASDAQ: MRTX) for $58.00 per share in cash, for a total

BMY

Analyst Ratings

4 Analysts Have This to Say About Xenon Pharmaceuticals

By Benzinga Insights

August 11, 3:26 PM

Within the last quarter, Xenon Pharmaceuticals (NASDAQ:XENE) has observed the following analyst ratings:

XENE

Wolfe Research Downgrades AbbVie to Peer Perform

Related Posts

Can AI Beat Humans In Understanding Language? Tencent And Alibaba’s AI Models Can

HC Wainwright & Co. Initiates Coverage On Icecure Medical with Buy Rating, Announces Price Target of $3

Bristol Myers Squibb Strengthens Oncology Portfolio With Mirati Therapeutics’ $5B Deal

4 Analysts Have This to Say About Xenon Pharmaceuticals